A micronutrient composition is highly effective in treating joint related inflammation and reducing ECM damaging enzymes in joints. The micronutrient composition comprises of Vitamin C, Vitamin E (D-alpha tocopherol), Vitamin B6, Vitamin D3, Folic acid, L-proline, L-lysine, Copper, Betaine HCl, Chondroitin sulfate, N-acetyl-glucosamine, Pycnogenol, SAMe, Cat's claw, Boswellia serrata, Stinging nettle and Glutamine. The micronutrient composition was most effective in supporting critical cellular mechanisms important for healthy joints-increased production and deposition of important ECM components by synovial cells and chondrocytes under pro-inflammatory conditions (presence of LPS). The micronutrient composition also decreased pro-inflammatory IL-6 and decreased secretion of MMP13, the ECM damaging enzyme in joints.
A micronutrient composition shown as Mix 1 comprises Rosemary extract at 1 mg-6,000 mg, Fenugreek extract 1 mg-50,000 mg and Fenugreek seed powder at 2 mg-8,000 mg, Cassia nomane seed extract powder 1 mg to 1,000 mg and dry extract 1 mg-300 mg, 3′3-di indolylmethylene 1 mg-800 mg, Zinc 0.1 mg-1,000 mg, Phosphatidylserine 1 mg-1,500 mg, Vitamin D 20 IU-10,000 IU, Vitamin C 10 mg-50,000 mg, Niacin 1 mg-3,000 mg, Theanine 0.1 mg-10,000 mg, Aspartic acid 10 mg-10,000 mg, Arginine 10 mg-50,000 mg and Dehydroepiandrosterone (DHEA) 1 mg-500 mg and Mix A comprising of all the ingredients of Mix 1 but does not contain DHEA and both are used improve men's health.
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/566 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol having an oxo group in position 17, e.g. oestrone
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
A micronutrient composition is highly effective in relaxing smooth muscle cells in bronchial cell and uterine cell during a specific disease. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9(folate) and vitamin B12, magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of smooth muscle cells important in providing much needed relief to breathe during airway constriction in asthma and uterine smooth muscle cell during premenstrual pain.
A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
5.
Micronutrient combination to reduce blood pressure
Vitex agnus-castus) 1-2,000 mg. The treatment by administering Mix 1 decreases estrogen dependent breast cancer cells proliferation and decrease in expression of cancer promoting cellular markers in cancer cells (iNOS, ApoE).
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
A23L 33/16 - Inorganic salts, minerals or trace elements
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A61P 5/24 - Drugs for disorders of the endocrine system of the sex hormones
7.
Micronutrient and plant extract composition and method of improving bone health
The micronutrient and plant extract composition comprises of a vitamin C, vitamin A (β-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methylsulfonylmethane (MSM) and stinging nettle extract and in combination it is used for treating, and reversing bone demineralization. The micronutrient and plant extract composition when administered to mammal with or without bone disease strengthens and helps in bone mineralization process. The composition can be used as a preventive dose for bone demineralization in human.
A micronutrient composition is highly effective in controlling high blood pressure while given to mammal for treating with or without prescribed pharmaceutical drug. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12 and calcium and magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of vascular smooth muscle cells important in maintaining healthy blood pressure. The combined effects of the micronutrients contained in the micronutrient composition include increased production of NO “relaxing factor” and decreased activity of Angiotensin converting enzyme 1 (ACE1). ACE1 inhibitory effect of this natural formula was more pronounced than obtained with the pharmaceutical ACE1 inhibitor—Lisinopril—the commonly prescribed high blood pressure medication.
A threefold decrease in α-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A shows significant effect on increased insulin secretion and glucose uptake by cells.
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 36/282 - Artemisia, e.g. wormwood or sagebrush
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 36/61 - Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A threefold decrease in α-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix B shows significant effect on increased insulin secretion and glucose uptake by cells.
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 36/282 - Artemisia, e.g. wormwood or sagebrush
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 36/61 - Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Ginseng, Pyrroloquinoline quinone, Gotu Kola in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
Avena sativa (green oat straw extract), Coenzyme Q10, NAD+, American Ginseng, and Pyrroloquinoline quinone in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Various combinations of formulas were used. Formulas 12, 10 and 5 shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A threefold decrease in α-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A and Mix B applied together with VitaminD+K2 shows significant effect on increased insulin secretion and glucose uptake by cells.
A61K 36/54 - Lauraceae (Laurel family), e.g. cinnamon or sassafras
A61K 36/87 - Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
A61K 36/282 - Artemisia, e.g. wormwood or sagebrush
Pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants
Pharmaceutical micronutrient composition including mixture D in this study helps to mitigate, inhibit, prevent and stop diseases caused by viral infections. The middle east respiratory syndrome-related coronavirus and severe acute respiratory syndrome-related coronavirus as well as their variants and mutants affecting mammals and causing infection are successfully treated using mixture D. Mixture D contains key micronutrients such as an ascorbate, N-acetylcysteine, theaflavins, resveratrol, cruciferous plant extracts, curcumin, quercetin, naringenin, and baicalin and a combination thereof. Additional micronutrients were tested with Mixture D and seemed to have beneficial effects.
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The study shows that ascorbic acid and its combination with some natural compounds could be included in developing preventive and therapeutic approaches toward the current pandemic. Some natural compounds were effective in lowering ACE2 cellular expression, with the highest inhibitory effects observed for baicalin (75%) and theaflavin (50%). Significantly, combinations of these and other test compounds with ascorbic acid further decreased ACE2 expression. The highest impact of ascorbate on ACE2 expression was noted when combined with theaflavin (decrease from 50% to 87%), zinc aspartate (decrease from 22% to 62%), and with 10-undecenoic acid (from 18% to 53%). Our study provides valuable experimental confirmation of the efficacy of micronutrients in controlling ACE2 expression—the coronavirus cellular “entry” point. It further validates the importance of nutrient interactions in various aspects of cellular metabolism and in considering potential therapeutic applications of nutrient-based approaches.
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A pharmaceutical composition in a physiological dose for a mammal is used for reducing vascular calcification caused due to statin consumption. The composition contains mixture 1 and statin. The mixture 1 contains combination of the Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic acid, Biotin, L-carnitine and Betaine. The mixture 1 can be used as a stand-alone product with or without statin.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
18.
Antibacterial and antifungal dental health formulation
Aronia melanocarpa extract, Fucoidan, Ginger extract, Zinc, Selenium, Alpha lipoic acid, White mulberry extract, Lychee fruit extract and Sour (Tart) cherry fruit extract are made for mammal consumption in liquid or solid form. This specific composition is used for increasing innate immunity in the mammal before and after the infection has occurred.
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
The invention discloses novel model of transgenic mammal, a method of crossbreeding transgenic mammal and the use of the transgenic mammal for assessing prevention and/or treatment methods for cardiovascular and other diseases related to lipoprotein(a). The transgenic mammal expresses human apolipoprotein (a) (apo(a)) and human apolipoprotein B-100 (apo B-100) genes and produces human lipoprotein (a), apo (a) and apo B-100 and produces no vitamin C. This novel dual transgenic mammal is the ideal model for testing pharmaceutical compounds for efficacy and usefulness in the prevention and/or treatment of human diseases.
A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates
A01K 67/027 - New or modified breeds of vertebrates
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides and peptidomimetics. The oligopeptides are used for making antibodies. The antibodies are used for diagnostic and treatment purposes of various diseases. In particular, the diseases may involve the mechanism of degradation of extracellular matrix by MMP's during cell proliferation cycle. Suppression of MMP activity seems to arrest tumor growth during cancer progression. MMP oligopeptides were used as vaccines to treat mice having murine melanoma B16FO induced tumor. There was a significant drop in tumor weight and size for the group of mice that were immunized with MMP oligopeptide.
The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides and peptidomimetics. The oligopeptides are used for making antibodies. The antibodies are used for diagnostic and treatment purposes of various diseases. In particular, the diseases may involve the mechanism of degradation of extracellular matrix by MMP's during cell proliferation cycle. Suppression of MMP activity seems to arrest tumor growth during cancer progression. MMP oligopeptides were used as vaccines to treat mice having murine melanoma B16FO induced tumor. There was a significant drop in tumor weight and size for the group of mice that were immunized with MMP oligopeptide.
patents